The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Efficacy of ropeginterferon in MF
Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, presents the safety and clinical activity data from a pilot study of ropeginterferon in patients with myelofibrosis (MF). The goal was to reduce the clonal burden and produce a hematologic response, especially in patients with early disease for whom there are limited treatment options. Ropeginterferon was well-tolerated and showed clinical improvement in half of the patients. Ongoing studies are warranted to further our understanding of its clinical benefit. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
